Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Vitamin D, D-binding protein, free vitamin D and COVID-19 mortality in hospitalized patients

Subramanian et al., The American Journal of Clinical Nutrition, doi:10.1093/ajcn/nqac027
Jan 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 27% treatment Improvement Relative Risk Mortality (b) 50% levels Mortality (c) 40% levels Vitamin D  Subramanian et al.  Prophylaxis Is prophylaxis with vitamin D beneficial for COVID-19? Prospective study of 467 patients in the United Kingdom Lower mortality with vitamin D (not stat. sig., p=0.12) c19early.org Subramanian et al., The American J. Cl.., Jan 2022 Favorsvitamin D Favorscontrol 0 0.5 1 1.5 2+
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020, now with p < 0.00000000001 from 122 studies, recognized in 9 countries.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 112 treatments. c19early.org
Retrospective 427 hospitalized COVID-19 patients in the United Kingdom, showing lower mortality with vitamin D supplementation (p=0.12), and higher mortality with both low and high vitamin D levels compared to a reference range of 50-74 nmol/L.
This is the 67th of 122 COVID-19 controlled studies for vitamin D, which collectively show efficacy with p<0.0000000001 (1 in 587 sextillion).
30 studies are RCTs, which show efficacy with p=0.0000032.
risk of death, 27.3% lower, RR 0.73, p = 0.12, treatment 31 of 131 (23.7%), control 80 of 336 (23.8%), adjusted per study, odds ratio converted to relative risk, prescribed supplement use, multivariable.
risk of death, 49.7% lower, RR 0.50, p = 0.02, high D levels 16 of 115 (13.9%), low D levels 33 of 118 (28.0%), NNT 7.1, adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, 50-74 nmol/L vs. <25nmol/L, multivariable, outcome based on serum levels.
risk of death, 39.7% lower, RR 0.60, p = 0.07, high D levels 16 of 115 (13.9%), low D levels 38 of 157 (24.2%), NNT 9.7, adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, 50-74 nmol/L vs. 25-49nmol/L, multivariable, outcome based on serum levels.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Subramanian et al., 31 Jan 2022, prospective, United Kingdom, peer-reviewed, 16 authors, dosage not specified.
This PaperVitamin DAll
Abstract: Vitamin D, D-binding protein, free vitamin D and COVID-19 mortality in hospitalized patients. Short title: Vitamin D and COVID-19 mortality PT Martin Hewison5, Rene F Chun6, Andrea Jorgensen7, Paul Richardson1, Darshan Nitchingham1, RI Joseph Aslan1, Maya Shah1, Coonoor R Chandrasekar8, Amanda Wood9, Mike Beadsworth10, Department of Gastroenterology, Liverpool University Hospital Foundation NHS Trust, Liverpool, N U 1 SC Munir Pirmohamed11 Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University M 2 A UK 3 IT ED of Liverpool Department of Clinical Chemistry, Liverpool University Hospital Foundation NHS Trust, Liverpool, UK Department of Biostatistics, Institute of Translational Medicine, University of Liverpool, ED 4 N Liverpool, UK Institute of Metabolism and Systems Research, University of Birmingham 6 Department of Orthopaedic Surgery, University of California, Los Angeles 7 Department of Health Data Science, University of Liverpool, Liverpool, UK 8 Department of Orthopaedic Surgery, Liverpool University Hospital Foundation NHS Trust, IN A L U 5 Department of Clinical Pharmacology, Liverpool University Hospital Foundation NHS Trust, O RI 9 G Liverpool, UK Liverpool, UK © Crown copyright 2022. This article contains public sector information licensed under the Open Government Licence v3.0 (http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/). Sreedhar Subramanian1, 2 ¶, Jonathan M Rhodes2, , Joseph M Taylor3, Anna M Milan3, Steven Lane4, 10 Tropical and Infectious Diseases Unit, Liverpool University Hospital Foundation NHS Trust, Liverpool, UK 11 Department of Molecular and Clinical Pharmacology, University of Liverpool ¶ Corresponding author: Consultant Gastroenterologist and Honorary Senior Lecturer PT Department of Gastroenterology RI Liverpool University Hospital Foundation NHS Trust and University of Liverpool SC Prescot Street Liverpool L7 8XP, UK N U Email: sreedhar.subramanian@liverpoolft.nhs.uk A Acknowledgements: None M Registration: The study protocol was approved by the London-Surrey Research Ethics Committee IT ED (20/HRA/2282). Funding Source: This research was funded by an internal departmental grant from Liverpool ED University Hospitals NHS Foundation Trust. The funders had no input into study design or final Guarantor of the article A L U Dr Sreedhar Subramanian N analysis. IN Author contributions: SS, JR, MP, JT and AM were involved in study design and initial drafting G of the manuscript. SL was involved in data analysis. All authors revised and approved the final O RI version of the manuscript. Sreedhar Subramanian, MD, FRCP Conflict of interest: JMR with the University of Liverpool and Provexis UK, holds a patent for use of a soluble fibre preparation as maintenance therapy for Crohn’s disease plus a patent for its use in antibiotic-associated diarrhoea. Patent also held with the University of Liverpool and others in relation to use of modified heparins in cancer therapy. SS has received speaker fees from MSD, Actavis, Abbvie, Dr Falk pharmaceuticals, Janssen, Takeda, Boehringer-Ingelheim, Shire and Abbvie, Dr Falk..
{ 'indexed': {'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T19:41:36Z', 'timestamp': 1643744496536}, 'reference-count': 0, 'publisher': 'Oxford University Press (OUP)', 'funder': [ { 'DOI': '10.13039/100010417', 'name': 'University Hospital Southampton NHS Foundation Trust', 'doi-asserted-by': 'publisher'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': [], 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>Vitamin D deficiency has been associated with worse coronavirus ' 'disease 2019 (COVID-19) outcomes but circulating 25-hydroxyvitamin D (25(OH)D) is largely ' 'bound to vitamin D binding protein (DBP) or albumin both of which tend to fall in illness ' 'making 25(OH)D status hard to interpret. Because of this, measurement of unbound “free” and ' 'albumin-bound “bioavailable” 25(OH) D has been proposed.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Objective</jats:title>\n' ' <jats:p>We aimed to examine the relationship between vitamin D status and ' 'mortality from COVID-19.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>In this observational study conducted in Liverpool, UK, ' 'hospitalized COVID-19 patients with surplus sera available for 25(OH)D analysis were studied. ' 'Clinical data including age, ethnicity and co-morbidities were extracted from case notes. ' 'Serum 25(OH)D, DBP and albumin concentrations were measured. Free and bioavailable 25(OH) D ' 'were calculated. Relationships between total, free and bioavailable 25(OH)D and 28-day ' 'mortality were analyzed by logistic regression.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Findings</jats:title>\n' ' <jats:p>Four hundred and seventy-two patients with COVID-19 were included, ' 'of whom 112 (23.7%) died within 28 days. Non-survivors were older (mean age 73, [range ' '34-98]) than survivors (65, [19-95]; P = 0.003) and more likely male (67%; P = 0.02). The ' 'frequency of vitamin D deficiency (25(OH)D &amp;lt;50nmol/L) was similar between ' 'non-survivors (71/112 [63.4%]) and survivors (204/360 [56.7%]; P = 0.15) but, after ' 'adjustment for age, sex and co-morbidities, increased odds for mortality were present in ' 'those with severe deficiency (25(OH)D &amp;lt;25nmol/L), OR 2.37 (95% CI 1.17, 4.78), or high ' '25(OH)D (≥100nmol/L), OR 4.65 (95% CI 1.51, 14.34) compared with 25(OH)D 50-74 nmol/L ' '(reference). Serum DBP levels were not associated with mortality after adjustment for ' '25(OH)D, age, sex and co-morbidities. Neither free nor bioavailable 25(OH)D were associated ' 'with mortality.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Conclusion</jats:title>\n' ' <jats:p>: Vitamin D deficiency as commonly defined by serum 25 (OH)D levels ' '(&amp;lt;50nmol/L) is not associated with increased mortality from COVID-19 but extreme low ' '(&amp;lt;25nmol/L) and high (&amp;gt;100nmol/L) levels may be associated with risk. Neither ' 'free nor bioavailable 25(OH) D associate with risk.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1093/ajcn/nqac027', 'type': 'journal-article', 'created': {'date-parts': [[2022, 1, 27]], 'date-time': '2022-01-27T20:11:33Z', 'timestamp': 1643314293000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': ['Vitamin D, D-binding protein, free vitamin D and COVID-19 mortality in hospitalized patients'], 'prefix': '10.1093', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-6483-1730', 'authenticated-orcid': False, 'given': 'Sreedhar', 'family': 'Subramanian', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Gastroenterology, Liverpool University Hospital ' 'Foundation NHS Trust, Liverpool, UK'}, { 'name': 'Department of Cellular and Molecular Physiology, Institute of ' 'Translational Medicine, University of Liverpool'}]}, { 'given': 'Jonathan M', 'family': 'Rhodes', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Cellular and Molecular Physiology, Institute of ' 'Translational Medicine, University of Liverpool'}]}, { 'given': 'Joseph M', 'family': 'Taylor', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Clinical Chemistry, Liverpool University Hospital ' 'Foundation NHS Trust, Liverpool, UK'}]}, { 'given': 'Anna M', 'family': 'Milan', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Clinical Chemistry, Liverpool University Hospital ' 'Foundation NHS Trust, Liverpool, UK'}]}, { 'given': 'Steven', 'family': 'Lane', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Biostatistics, Institute of Translational ' 'Medicine, University of Liverpool, Liverpool, UK'}]}, { 'ORCID': 'http://orcid.org/0000-0001-5806-9690', 'authenticated-orcid': False, 'given': 'Martin', 'family': 'Hewison', 'sequence': 'additional', 'affiliation': [ { 'name': 'Institute of Metabolism and Systems Research, University of ' 'Birmingham'}]}, { 'given': 'Rene F', 'family': 'Chun', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Orthopaedic Surgery, University of California, Los ' 'Angeles'}]}, { 'given': 'Andrea', 'family': 'Jorgensen', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Health Data Science, University of Liverpool, ' 'Liverpool, UK'}]}, { 'given': 'Paul', 'family': 'Richardson', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Gastroenterology, Liverpool University Hospital ' 'Foundation NHS Trust, Liverpool, UK'}]}, { 'given': 'Darshan', 'family': 'Nitchingham', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Gastroenterology, Liverpool University Hospital ' 'Foundation NHS Trust, Liverpool, UK'}]}, { 'given': 'Joseph', 'family': 'Aslan', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Gastroenterology, Liverpool University Hospital ' 'Foundation NHS Trust, Liverpool, UK'}]}, { 'given': 'Maya', 'family': 'Shah', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Gastroenterology, Liverpool University Hospital ' 'Foundation NHS Trust, Liverpool, UK'}]}, { 'given': 'Coonoor R', 'family': 'Chandrasekar', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Orthopaedic Surgery, Liverpool University Hospital ' 'Foundation NHS Trust, Liverpool, UK'}]}, { 'given': 'Amanda', 'family': 'Wood', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Clinical Pharmacology, Liverpool University ' 'Hospital Foundation NHS Trust, Liverpool, UK'}]}, { 'given': 'Mike', 'family': 'Beadsworth', 'sequence': 'additional', 'affiliation': [ { 'name': 'Tropical and Infectious Diseases Unit, Liverpool University ' 'Hospital Foundation NHS Trust, Liverpool, UK'}]}, { 'ORCID': 'http://orcid.org/0000-0002-7534-7266', 'authenticated-orcid': False, 'given': 'Munir', 'family': 'Pirmohamed', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Molecular and Clinical Pharmacology, University of ' 'Liverpool'}]}], 'member': '286', 'published-online': {'date-parts': [[2022, 1, 31]]}, 'container-title': ['The American Journal of Clinical Nutrition'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://academic.oup.com/ajcn/advance-article-pdf/doi/10.1093/ajcn/nqac027/42357837/nqac027.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'https://academic.oup.com/ajcn/advance-article-pdf/doi/10.1093/ajcn/nqac027/42357837/nqac027.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T19:08:49Z', 'timestamp': 1643742529000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 1, 31]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.1093/ajcn/nqac027', 'relation': {}, 'ISSN': ['0002-9165', '1938-3207'], 'issn-type': [{'value': '0002-9165', 'type': 'print'}, {'value': '1938-3207', 'type': 'electronic'}], 'subject': ['Nutrition and Dietetics', 'Medicine (miscellaneous)'], 'published': {'date-parts': [[2022, 1, 31]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit